Latest news
Loading news…
Kynos Therapeutics
ClosedOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down.🔥 MediumHeat score — how much recent activity & attention the company has (web traffic, news, hiring). Edinburgh, Edinburgh, City of, United Kingdom Founded 2020 1-10 employees For Profit
Kynos Therapeutics develops KMO inhibitors across key indications in inflammation, immunity, and metabolism.
Kynos Therapeutics was acquired by Dr. Falk Pharma in 2024.
Total Funding
Available in Pro Last Funding
Available in Pro Acquisitions
0
Monthly Visits
Available in Pro Contacts
1
Patents
5
Company Details
Funding & Financials
Pro- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
IPO & Stock
- IPO status
- Private
Web Traffic
Pro- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Technology & IP
- Active technologies
- 7
- Patents granted
- 5
- Trademarks
- 0
- Top patent class
- Organic Chemistry
- IT spend
- $540K
Company Info
- Founded
- 2020
- Employees
- 1-10
- Operating status
- Closed
- Company type
- For Profit
- Org types
- company
- News articles
- 17
- HQ
- Edinburgh, Edinburgh, City of, United Kingdom
- Region
- Europe, Middle East, and Africa (EMEA)
- Exit date
- Oct 29, 2024
- Closed
- Jan 1, 2024
Signals & Scores
- Heat score
- Medium
- Trend (7d)
- 0
- Trend (30d)
- -0.6
- Trend (90d)
- 1.8
1
professional contacts at Kynos Therapeutics
Contact execs at Kynos Therapeutics →Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Recent News related to Kynos Therapeutics
Loading news…
FAQs about Kynos Therapeutics
People who checked this page also checked these
Browse the full Acquirezy directory.